Abdul Rafeh Naqash

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer

Bairavi Shankar, Jiajia Zhang, Abdul Rafeh Naqash et al. · JAMA Oncology · 2020 · 489 citations · Full text

Medicine, Immunology, Oncology +17

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

Chipman Stroud, Aparna Hegde, Cynthia R. Cherry et al. · Journal of Oncology Pharmacy Practice · 2017 · 328 citations

Pharmacy, Immunology, Pharmacotherapy +17

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study

Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida et al. · Hepatology · 2022 · 234 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +11

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

Hamzah Abu‐Sbeih, David M. Faleck, Biagio Ricciuti et al. · Journal of Clinical Oncology · 2019 · 199 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

Hamzah Abu‐Sbeih, Faisal S. Ali, Abdul Rafeh Naqash et al. · Journal of Clinical Oncology · 2019 · 197 citations · Full text

Life Sciences, Immunology, Oncology +17